Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three studies. The post Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops appeared first on Investor's Business Daily.
Neumora Therapeutics' depression drug fails to meet main goal of late-stage study
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study.
Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed significant efficacy in a phase 2 study for MDD and is also being tested for bipolar depression, with phase 2 data expected in late 2025. Neumora has $341.3 million in cash, enough to fund operations until mid-2026, minimizing near-term dilution risk unless management opts otherwise.
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch – President and Chief Executive Officer Josh Pinto – Chief Financial Officer Rob Lenz – Head of Research and Development Conference Call Participants Julian Pino – Stifel Brian Abrahams – RBC Capital Markets Myles Minter – William Blair Charles Wang – Mizuho Douglas Tsao – H.C. Wainwright Charlie Yang – Bank of America Operator Ladies and gentlemen, thank you for standing by.
